

Estimating Under-diagnosis of Patients in Chronically-ill Populations

Andrew Stocking PhD¹ Ian Duncan PhD FSA MAAA² and Nhan Huynh PhD³

Address Correspondence to: Ian Duncan, Dept. of Statistics & Applied Probability, UCSB, South Hall 5518, Santa Barbara, CA 93106. Email: duncan@pstat.ucsb.edu. Phone #: 805-893-6023

Conflicts of Interest: None

Source of Funding: Funding for this paper was provided by PBE Inc.

The Office of Research Human Subjects Department at UCSB reviewed this work and determined that it did not meet the criteria for human subjects research as defined in the Common Rule (45 CFR 46). IRB review and oversight are not required because the activity does not involve “human subjects” as defined under 45 CFR 46.102 and the research team is not accessing identifiable private information.

ABSTRACT

Diagnosis coding in administrative data is known to be inconsistent and incomplete, introducing inaccurate assessment of patients’ health outcomes. The under-diagnosis of members with a target chronic condition reduces the correlation of that chronic condition with associated events. Yet, only a few studies have evaluated the extent of under-reporting of chronic conditions in administrative data. In this study, we developed a novel framework to identify latent members, or those who have not yet been identified with a target chronic condition through claims-based diagnosis but are likely to have some degree of the condition. We applied our innovative approach to estimate the prevalence of a chronic-related event, based on the population of observed and latent members. We provided a detailed illustration that treats incontinence as our target chronic condition while examining four types of incontinence-related events: urinary-tract infections (UTIs), slips and falls, dermatitis, and behavioral disruptions. All analysis relied on the 5% Medicare sample for a continuously enrolled cohort between 2014-2018. Using our novel approach, we were able to increase our identification of incontinence from the 11.2% diagnosed in 2018 to an estimated prevalence in 2018 of 34.7% among fee-for-service Medicare beneficiaries over the age of 65. Similarly, our estimation of UTIs associated with those with incontinence increased from 38% to 68%, from 20% to 41% for IAD, 22% to 54% for slips and falls, and from 26% to 57% for behavior disruptions.

¹ Principle Business Enterprises, Inc.

² Department of Statistics and Applied Probability, University of California Santa Barbara

³ Santa Barbara Actuaries Inc.

BACKGROUND

Many studies of chronically-ill populations use administrative data (claims) rather than clinical records because of the availability of large, curated datasets (and corresponding unavailability of large clinical datasets). The issue with claims-based identification of incidence and prevalence of a chronic condition is that it depends on the claim-based coding of the condition during the period of observation. Coding practices vary, as do patient compliance and provider access, resulting in incomplete annual coding of conditions. Some reimbursement systems, such as Medicare Advantage’s risk-adjusted payments that depend on patient risk profiles as identified through claims-based diagnoses provide direct incentives to providers for complete and accurate coding and disincentives for inaccurate or exaggerated coding. This is not true, for example, of the Medicare fee-for-service population, as demonstrated amply in the literature [1-5]. We propose a method to identify more accurately the true prevalence of patients with a chronic condition in a claims dataset by identifying those we call “latent” members, members who likely have the condition who are not currently identified through claims but who will be identified in the future (or have been previously). We demonstrate the method with an application to patients with incontinence.

Incontinence is likely to be a more extreme case of under-reporting for several reasons. First, for many people, incontinence often begins light and becomes more severe over time. For example, stress incontinence occurs because of a weak pelvic floor that can cause bladder to leak during exercise, coughing, sneezing, laughing, or any body movement that puts pressure on the bladder. This type of incontinence can be under-reported because it may be embarrassing to discuss, is not observed during a primary care visit, or may be considered a natural part of the aging process [6, 7]. Second, there is no HCC group for incontinence in the CMS reimbursement model, further reducing the incentive to report it. That is, even within the MA setting there is no reimbursement benefit to an incontinence diagnosis which reduces the likelihood that primary care providers or other providers have developed methods to accurately identify incontinence.

Estimation of under-diagnosis and under-reporting of chronic conditions

The issue of under-coding and over-coding has been studied intensively in Medicare. Medicare fee-for-service physicians are reimbursed on the basis of resource value units for each CPT code that they submit.⁴ Although a diagnosis is required for a claim to be reimbursed, only a single diagnosis is required for physician services. Furthermore reimbursement is based on *units of work* as embodied in the CPT code rather than the patient complexity (comorbidity conditions). A physician can see a complex polychronic patient 100 times a year and provide a diagnosis of diabetes for every visit and be paid the same amount (for the same CPT code), even though the

⁴ Resource value units, or resource-based relative value scale is a Marxian labor-value theory concept introduced by William Hsiao in the late 1980s. (Hsiao WC, Braun P, Dunn D, Becker ER. Resource-Based Relative Values: An Overview. *JAMA*. 1988;260(16):2347–2353).

patient has six other comorbidities that contribute to their health. The patient's comorbid heart condition, hypertension and other conditions are not required for reimbursement and will not be recorded. Fee-for-service reimbursement, therefore, does not provide an incentive for recording patient diagnoses and complexity. The fee-for-service system rewards the "inputs" of care regardless of patient complexity or clinical outcome. Medicare Advantage (MA) plans, conversely, are reimbursed on the basis of a risk-adjusted premium. Risk adjustment takes account of a member's conditions, as long as they are recorded in claims. MA plans are likely to record a more complete range of diagnosis codes than FFS Medicare (See for example [1-5, 8-12]).

Applying to the model a broader range of recorded diagnoses for an individual with otherwise equivalent risk factors (including health status) is likely to result in a higher risk score for the individual with the wider range of diagnoses.⁵

As discussed above, Congress has recognized that differences in coding ("coding intensity") will potentially result in non-equivalence between a plan's members and members with the same health profile in FFS Medicare; and, for this reason, requires a coding pattern adjustment in MA. Differences exist not just in coding intensity between fee-for-service and MA systems but also between different providers in the MA system. Even with more complete coding, patients do not always seek treatment for their conditions on an annual basis (the typical time-period of a population-based study). This leads to under-reporting of chronic conditions, even when coding is complete. An example from the early 2000s (Duncan [12]; see Kronick [11] for a more recent example) illustrates this issue. Table 1 compares the patients identified in adjacent years using three algorithms: Narrow (medical claims with 2 or more encounters for the same diagnosis in the year), Broad (medical claims with 1 or more encounters for the same diagnosis in the year) and Rx (Broad definition + 3 or more prescriptions for an appropriate medication). As the table shows, using a typical (narrow) definition only three-quarters of patients re-identify in a second year; even with a very broad definition all patients are not re-identified.

A second source of identification of under-reporting of chronic patients is the comparison of claims-based identification with national statistics. This type of comparison should be approached with caution because national statistics include patients from a variety of payers (including Medicare, Medicaid, Commercially-insured (employer) populations and the uninsured). As an example, prevalence of urinary incontinence (UI) in a sample of 1,243,173 Medicare fee-for-service lives over age 65 amounted to 11.2%, compared with national statistics of 60% for women and 35% for men [13].

⁵ The effect of a broader range of recorded diagnoses will depend on the mapping of diagnoses to HCCs, however. Diagnoses that map to the same HCC would not affect the member's risk score; diagnoses that map to a more severe HCC within the same diagnostic category, or that map to a different HCC would increase the risk score.

Prevalence of Claims-based identification in a Chronic Population					
Year 1		Narrow	+ Broad	+ Rx	TOTAL
Year 2	Narrow	75.9%			
	+ Broad		85.5%		
	+ Rx			92.9%	
	Not Identified	24.1%	14.5%	7.4%	
	TOTAL	100.0%	100.0%	100.0%	100.0%

Table 1: Identification of Chronic Patients in Adjacent Years

METHODOLOGY

Estimating prevalence of chronic conditions


Recognizing that true prevalence of a chronic condition through claims may be underestimated, we propose a method for estimating prevalence. We do so using an historical cohort of patients. We identify a longitudinal cohort of continuously enrolled members of the population in Δ years where C_t represents the number of members in the baseline year t . Note that our setup of using a continuous cohort helps simplify the estimation approach but under-estimation is still possible (see Discussion section for further explanations). With this setup, the size of our cohort remains constant over Δ years of the study: $C_t = C_{t+i}$ for $i = 0, \dots, \Delta - 1$. Let $N_{t,t+i}^{obs}$ be the observed number of members who are newly-diagnosed with the target condition in year $t+i$ ($i = 0, \dots, \Delta - 1$) and experienced the condition-related events in the baseline year t . We illustrate our setup in Figure 1.

Let N_t be the *true* number of members who should have been diagnosed with the target condition in the baseline year t . We can express N_t as follows:

$$\begin{aligned}
 N_t &= \sum_{i=0}^{\Delta-1} N_{t,t+i}^{obs} = N_{t,t}^{obs} + \sum_{i=1}^{\Delta-1} N_{t,t+i}^{obs} \\
 &= N_{t,t}^{obs} + N_t^{latent} \\
 &= N_t^{obs} + N_t^{latent}
 \end{aligned} \tag{1.1}$$

In Eq. (1.1), N_t can be decomposed into the observed number of members diagnosed with the condition in the baseline year t (N_t^{obs}) and the latent number of members in the baseline year t (N_t^{latent}). Intuitively, we identify the latent members by adding up all cases of members with the delayed diagnosis of the condition in all future years $t+i$ ($i = 1, \dots, \Delta - 1$).

Figure 1: Timeline of members diagnosed with the target chronic condition during the study



Let p_t^{obs} be the observed prevalence of the target condition in the baseline year t , then we can express the prevalence in terms of the number of members in the cohort identified with the condition and the size of the cohort, $p_t^{obs} = \frac{N_t^{obs}}{C_t}$. Similarly, we denote p_t as the *true* prevalence of the target condition in year t and $p_t = \frac{N_t}{C_t}$. The ratio of the true prevalence to the observed prevalence is:

$$\frac{p_t}{p_t^{obs}} = \frac{N_t}{N_t^{obs}} \quad (1.2)$$


Looking into the future year k ($k > t$), the relationship between the true and the observed number of members diagnosed with the condition can be expressed as: $N_k = \left(\frac{p_k}{p_k^{obs}} \right) \times N_k^{obs}$. Assuming the prevalence ratio in year k remains the same as in the baseline year t and the pattern of under-coding in fee-for-service claims persists, we can partially estimate the members identified with the chronic condition in year k as:

$$N_k \approx \left(\frac{p_t}{p_t^{obs}} \right) \times N_k^{obs}.$$

Effect of under-diagnosis on the reporting of associated events

The under-identification of members with the condition results in corresponding under-attribution of associated events to the chronic condition.⁶ The attribution of events matters for different reporting purposes, particularly for quality reporting and for the types of contracts that rely on quality measures.

Figure 2: Association between chronic-related events and members diagnosed with the condition in the study



Appropriately attributing events to identified latent members

Let M_t^{obs} be the observed number of events associated with members identified with the condition in the baseline year t . Then, the relationship between M_t^{obs} and N_t^{obs} is:

$$M_t^{obs} = N_t^{obs} (\rho_t^{obs})(\gamma_t^{obs}) \quad (1.3)$$

where ρ_t^{obs} is the frequency of members diagnosed with the condition experiencing the event in the baseline year t and γ_t^{obs} is the conditional average number of event encounters. When the target chronic condition is decomposed into multiple types (e.g. diabetes with three hierarchical groupings in the CMS-HCC risk adjustment models), Eq. (2) can be generalized as follows to incorporate different types of the chronic condition:

$$M_t^{obs} = \sum_s^{\text{Condition types}} N_t^{obs} (\rho_t^{obs}) (\gamma_t^{obs}) \quad (1.4)$$

In Eq (1.4) above:

⁶ For hospital admissions this may not be a significant issue given that hospital claims report a range of diagnoses. Reporting by physicians may be affected in the same way as prevalence.

- ${}^s N_t^{obs}$ represents the observed number of members with the type- s condition and
- $$\sum_s {}^s N_t^{obs} = N_t^{obs}$$
- ${}^s \rho_t^{obs}$ is the frequency of members diagnosed with the condition type s experiencing the event
 - ${}^s \gamma_t^{obs}$ is the conditional average number of event encounters for members with the target condition type s .

We denote M_t as the total count of the chronic-related event in the baseline year t . Calculating M_t involves two populations: members diagnosed with the condition in the baseline year t while experiencing the event in the same year and members with the delayed diagnosis in the future years $t+i$ ($i=1, \dots, \Delta-1$) while experiencing the events in the baseline year t (See Table 2 for illustration). Employing similar setup described in Eq. (1.1), we can express M_t as follows:

$$\begin{aligned} M_t &= \sum_{i=0}^{\Delta-1} N_{t,t+i}^{obs} \rho_{t,t+i}^{obs} \gamma_{t,t+i}^{obs} \\ &= N_{t,t}^{obs} \rho_{t,t}^{obs} \gamma_{t,t}^{obs} + \sum_{i=1}^{\Delta-1} N_{t,t+i}^{obs} \rho_{t,t+i}^{obs} \gamma_{t,t+i}^{obs} \\ &= M_{t,t}^{obs} + M_{t,t}^{latent} \\ &= M_t^{obs} + M_t^{latent} \end{aligned} \quad (1.5)$$


Through the claims-based diagnosis in the baseline year t , M_t^{latent} can be thought of as the number of events associated with members without a claims-identified target condition. Thus, under-identification of members with the condition can under-estimate the prevalence of events attributable to the condition population and over-estimate the events in the non-condition population, see Figure 3.

We can infer the relationship between the total and the observed number of chronic-related events in future year k ($t < k \leq \Delta-1$) and the baseline year t :

$$M_k = \left(\frac{M_t}{M_t^{obs}} \right) \times M_k^{obs} \quad (1.6)$$

In the above equation, M_k^{obs} is the observed number of the chronic-related events in the year k and M_k is the total number of the chronic-related events in year k . Note that M_t^{obs} and M_k^{obs} are straightforward to estimate using claims-based diagnosis in year t and k , respectively; while M_t can be estimated using calculation approach in Eq. (1.5).

Figure 3: Effect of under-diagnosis on the reporting of associated events



AN APPLICATION TO THE UNDER-DIAGNOSIS OF INCONTINENCE

Study design

For this study, we evaluated the extent of under-reporting of the prevalence of urinary incontinence (UI) as a result of using a claims-based identification algorithm. We identified urinary incontinence (UI) and fecal incontinence (FI) using ICD-10 codes in the R and N series (see Appendix A). We then estimated the extent of under-reporting of incontinence in a Medicare fee-for-service dataset, limited to members aged 65 and older, by analyzing a continuously enrolled patient cohort. We also required at least 3 months of enrollment in each year per member to reduce duration bias caused by beneficiaries who have minimal exposure to Medicare. All results in our illustration were generated using SAS software version 9.4.

Year of Initial UI Diagnosis	2014	2015	2016	2017	2018	Total
Eligible Members	833,614	833,614	833,614	833,614	833,614	833,614
No. of Incident Members in Year	66,510	40,598	36,518	34,116	34,030	211,772
In 2014, Number of Years until Initial UI Diagnosis	0	1	2	3	4	-
% of members with UI by year of diagnosis	31.4%	19.2%	17.2%	16.1%	16.1%	100.0%
Share of continuously enrolled Members	8.0%	4.9%	4.4%	4.1%	4.1%	25.4%

Table 2: Identification of Incident UI Members by Year

We determined the incidence of four types of incontinence-related events for each cohort: 1) UTIs, 2) Incontinence Associated Dermatitis or Perineal Dermatitis (IAD), 3) Slips, falls and related fractures, and 4) Behavioral disruptions (See Appendix A). Incidence for each event is calculated

as the share of members within each cohort who experienced at least one event in the year of the UI/FI diagnosis.

Estimation of incontinent prevalence

In total there were 833,614 patients continuously enrolled between 2014 and 2018. Thus, the baseline year in this illustration is $t=2014$, size of our cohort in the baseline year is $C_{2014} = 833,614$, and duration of the study is $\Delta = 5$ years. We attributed the patient to the year of first identification with an incontinence diagnosis (excluding FI). The resulting patient numbers can be seen in Table 2. In 2014, we have identified 66,510 members with incontinent diagnosis and the remaining 767,104 out of 833,614 patients do not have any incontinence claim ($N_{2014}^{obs} = 66,510$). In the following year, of the 767,104 patients 40,598 are identified as incontinent through claims while having incidence of incontinence-related events in 2014 ($N_{2014,2015}^{obs} = 40,598$). Our hypothesis is that the majority of these patients suffered from some form of incontinence the previous year but had not sought medical help (or generated a claims-based diagnosis) in 2014. By 2018, the last year for which we have data, $N_{2014,2018}^{obs} = 34,030$.

Applying Eq. (1.1), we can estimate the total number of members who should have identified with incontinence in the baseline year 2014:

$$\begin{aligned} N_{2014} &= \sum_{i=0}^4 N_{2014,2014+i}^{obs} = N_{2014}^{obs} + \sum_{i=1}^4 N_{2014,2014+i}^{obs} \\ &= 66,510 + (40,598 + \dots + 34,030) \\ &= 211,772 \end{aligned}$$

We have identified 145,262 ($= 211,772 - 66,510$) latent members in 2014. The ratio between the true and the observed prevalence of incontinence in 2014 is $p_{2014} / p_{2014}^{obs} = 211,772 / 66,510 \approx 3.184$. Analyzing 2018 claims data, the number of incident patients identified is ${}^{UI,DI}N_{2018}^{obs} = 133,502$ (excluding FI members). Thus, we can estimate the ultimate number of condition members that will emerge within the following four years from 2018 incidence cohort as:

$$N_{2018} \approx \left(\frac{p_{2014}}{p_{2014}^{obs}} \right) \times {}^{UI,DI}N_{2018}^{obs} + {}^{FI}N_{2018}^{obs} = 3.184 \times 133,502 + 6,004 = 431,074$$

The 2018 latent UI/DI members is ${}^{UI,DI}N_{2018}^{latent} = {}^{UI,DI}N_{2018} - {}^{UI,DI}N_{2018}^{obs} = 291,568$ and the prevalence of incontinence is $431,074 / 1,243,173 \approx 34.7\%$.

Estimation of prevalence of incontinence-related events: UTI, Slips & Falls, Dermatitis, and Behavioral Disruptions

Identification of latent members allows us more accurately to assign the complications of events associated with incontinence to the incontinent and latent incontinent population. Exacerbations that are associated with UI/FI are urinary tract infections, slips and falls, dermatitis and behavior disruptions [14-17]. We reported the frequency of these events among the 2018 incident patients in Table 3. Let us further assume that the distribution of 2018 latent population is the same as the 2014 cohort (Table 2) and the latent members emerge with claims-based diagnoses between 2019-2022 with the same frequency as the 2014 cohort.

Consider UTI as the incontinence-event of interest. From Table 3, the observed number of UTIs associated with members diagnosed with UI/DI in 2018 is $^{UI,DI}M_{2018}^{obs} = 233,625$. Applying Eq. (1.6), we can approximate the total number of UTIs in 2018 such as:

$$M_{2018} = \left(\frac{M_{2014}}{M_{2014}^{obs}} \right) \times ^{UI,DI}M_{2018}^{obs} + ^{FI}M_{2018}^{obs}$$

Based on retrospective data analysis in Table 4, we can infer the following:

- $M_{2014}^{obs} = N_{2014}^{obs} \times \rho_{2014}^{obs} \times \gamma_{2014}^{obs} = 66,510 \times 0.435 \times 5.40 = 156,232$
- $M_{2014} = \sum_{i=0}^4 N_{2014,2014+i}^{obs} \times \rho_{2014,2014+i}^{obs} \times \gamma_{2014,2014+i}^{obs} = 275,761$

Therefore, $M_{2018} = (275,761 / 156,232) \times 233,625 + 6,002 \approx 418,367$. And $^{UI,DI}M_{2018}^{latent} = 178,740$ is the number of UTIs associated with the latent UI/DI incontinent. If only UTI events of the observed patients are counted, UTI event prevalence is 38.6% ($M_{2018}^{obs} / 621,349$); estimating UTI events for the latent incontinence increases UTI prevalence due to the incontinent population to 67.3% ($M_{2018} / 621,349$). Table 5 summarizes the results for other incontinence-related events using our proposed analysis.

2018	Urinary Incontinence	Fecal Incontinence	Dual Incontinence	Total Incontinence	Total Non-Incontinence	Total Events
Members with the condition	125,412	6,004	8,090	139,506	1,103,667	-
Events related to Incontinence						
UTI	211,886	6,002	21,739	239,627	381,721	621,349
IAD	16,030	830	1,762	18,622	73,349	91,971
Slips & Falls	313,600	13,506	34,827	361,933	1,267,154	1,629,088
Behavior disruptions	34,064	1,224	6,528	41,817	117,693	159,510

Table 3: Incontinence-event Frequencies in 2018

Year of Initial UI Diagnosis	2014	2015	2016	2017	2018	Total
Eligible Members	833,614	833,614	833,614	833,614	833,614	833,614
No. of Members initially diagnosed in Year	66,510	40,598	36,518	34,116	34,030	211,772
In 2014, Number of Years until Initial UI Diagnosis	0	1	2	3	4	-
Share of total members with UI	31.4%	19.2%	17.2%	16.1%	16.1%	100.0%
Share of continuously-enrolled Members	8.0%	4.9%	4.4%	4.1%	4.1%	25.4%
UTI Prevalence in 2014	43.5%	27.0%	22.6%	19.7%	17.7%	-
Cond. Average UTI Encounters	5.40	4.09	3.62	3.55	3.48	-
IAD Prevalence in 2014	2.6%	1.7%	1.4%	1.2%	1.0%	-
Cond. Average Dermatitis Encounters	1.62	1.53	1.51	1.58	1.57	-
Fall Prevalence in 2014	38.7%	33.7%	31.0%	29.4%	28.1%	-
Cond. Average Fall Encounters	6.58	5.76	5.56	5.62	5.35	-
Behavioral Prevalence in 2014	1.8%	1.3%	1.0%	0.9%	0.9%	-
Cond. Average Behavioral Encounters	4.12	3.85	4.04	3.93	4.05	-

Table 4: Identification of Incontinence Incidence in the 2014 Cohort

Events related to incontinence	M_{2014}^{obs}	M_{2014}	M_{2018}^{obs}	M_{2018}	$\left(\frac{M_{2018}^{obs}}{\text{Total events}} \right)$	$\left(\frac{M_{2018}}{\text{Total events}} \right)$
UTI	156,232	275,761	239,627	422,959	38.6%	68.1%
IAD	2,801	5,810	18,622	38,627	20.2%	41.0%
Slips and falls	169,365	418,641	361,933	894,636	22.2%	53.7%
Behavior disruptions	4,932	10,887	41,817	9,229	26.2%	56.9%

Table 5: Summary of latent analysis for events related to incontinence

DISCUSSION

The novel approach presented here is able to increase the prevalence of a chronic condition without seeking additional datasets for the same members (e.g., clinical or drug databases). The approach rests on several assumptions. First, the approach relies on the hypothesis that the chronic condition is unlikely to develop within a short period of time. That is, the chronic condition is likely to exist one to five years prior to a formal diagnosis. Second, our approach relies on applying a retrospective setting to the future state. Changes in incentives or information that affect the propensity of providers to diagnose a chronic condition will cause the retrospective approach to be a less accurate prediction for the future.

Considering these two assumptions in the context of incontinence highlights the benefit of the approach. First, we assumed that incontinence often begins light and becomes more severe over time, presumably leading to nearly everyone with an incontinent diagnosis in 2018 also being incontinent in the preceding 5 years, albeit possibly to a lesser degree, but without a confirmed claims-based diagnosis. This assumption is supported by the evidence that incontinent in the elderly is a chronic condition that is likely to exist 1 to 5 years prior to a formal diagnosis [18-20].

The results from Table 4 provide further support for this assumption. We find that as patients are further from the year of their first claims-based incontinence diagnosis, the prevalence of the incontinence-related events monotonically decreases, and the conditional average number of events also tends to decrease. In all cases, the incidence and conditional average for incontinence-related events was lowest for those furthest from the year in which they would be diagnosed with incontinence and increased up until the year of diagnosis. This provides some evidence that those diagnosed in later years as incontinent were experiencing the same set of incontinence-related events in 2014 as those who were diagnosed in 2014, only to a lesser extent.

These results provide some insights into a possible additional underlying cause of under-reporting of chronic conditions. They suggest that maybe the clinical diagnosis is incomplete because healthcare providers treat the symptoms without diagnosing the underlying cause. But when the frequency of symptoms increases above a threshold level, providers are more likely to include the related diagnosis in the claim. With respect to incontinence, the data shows a clear trend that as the incidence of each of these incontinence-related events increases, so does the likelihood of a claim-based diagnosis of incontinence.

Second, we assumed that there were no changes in the incentive or information to diagnose incontinence or the incontinence-related events. We analyzed diagnoses of a continuously-enrolled cohort of members between 2014-2018 to estimate the prevalence of latent incontinence in 2018. Our calculations assume the 2018 latent population is the same as the 2014 cohort and the latent members emerge with claims-based diagnoses between 2019-2022 with the same frequency as the 2014 cohort. We believe this to be true for the chronic condition of incontinence; between 2014 and 2018, no new ICD-10-CM codes were created and no new incentives were added to diagnose incontinence. The same is true for UTIs, slips and falls, and behavioral disruptions. However, this was not true for IAD, which had a new ICD-10-CM code developed and added in 2016.⁷ For that reason, the use of this method for predicting the true prevalence of IAD in 2018 may be limited.

Limitations

Our proposed framework is subjected to several limitations. First, we did not have external data such as clinical or drug records for the same patients to validate and compare our results. However, these datasets are expensive to obtain and for certain chronic conditions, patients are not treated with medication. Second, our approach could still underestimate the size of the latent population due to limited data and the study design. We could not assess the latent members beyond the data period available to us. Our setup of following a continuously enrolled cohort does not allow for the exit of members due to death. For example, if someone were diagnosed after the first year in question, but died prior to the end of the study period, they would be missed in the count of the true prevalence of the chronic condition for the base year. Although considering member exists from the examined cohort could bring us closer to the true prevalence, it requires a more complex estimation approach which is beyond the scope of this paper. Our main objective is to assess the under-diagnosis of the chronic condition and improve the observed prevalence by identifying more

⁷ https://www.icd10data.com/ICD10CM/Codes/Changes/New_Codes/134?year=2016

members who should have not experienced the delayed diagnosis. Finding the best estimation technique to identify latent members can be a subject of interest for other future studies. Third, the analysis relies on the assumption that the distribution of latent population in a future year is the same as the baseline cohort. This means the underlying populations for both cohorts should be similar. Proper methods must be conducted to validate this assumption.

CONCLUSION

This is the first study to propose an innovative approach to estimate the true prevalence of the target chronic disease using administrative data. Using incontinence in our illustration, we measured the degree of under-diagnosis of incontinence in the Medicare 5% sample by comparing the observed prevalence against the reported prevalence in the literature. We showcased the implication of under-diagnosis of members with the chronic condition can result in substantial under-count of the associate events. Thus, it is critical for future studies to validate their results when examining prevalence of chronic diseases and comorbidities in administrative data. Understanding the policy or cost implications of these missing diagnoses is a topic of future research and could be applied to many chronic conditions such as obesity and COPD.

Appendix A. ICD-10 Diagnosis Code List for Incontinence and Related Conditions

Condition	ICD-9 Diagnosis Code	ICD-10 Diagnosis Code
Urinary Incontinence	788.30	R32 Unspecified urinary incontinence
	788.63	R39.15 Urge Incontinence
	788.91	R39.81 Functional urinary incontinence
	596.54, 596.59	N31.9 Neurogenic Bladder
	596.51	N32.81 Overactive bladder
	596.6, 596.7, 596.89	N32.89 Bladder spasm
	625.6, 788.32	N39.3 Stress incontinence (female) (male)
	788.31	N39.41 Urge incontinence
	788.34	N39.42 Incontinence without sensory awareness
	788.33	N39.46 Stress and Urge incontinence
	788.36	N39.44 Nocturnal urinary Incontinence
	N/A	N39.492 postural (urinary) incontinence
	788.39	N39.498 reflex urinary incontinence
Fecal Incontinence	*	R15 Fecal incontinence
	*	R15.0 Incomplete defecation
	*	R15.1 Fecal smearing
	*	R15.2 Fecal urgency
	*	R15.9 Full incontinence of feces
	*	R98.1 Fecal incontinence, nonorganic origin
	*	K59.2 Neurogenic Bowel
Urinary Tract Infections	599.0	N39.0 Urinary tract infection, site not specified
	595	N30 Cystitis
	597.0, 099.4, 597.8	N34 Urethritis and urethral syndrome
Incontinence Associated Dermatitis or Perineal Dermatitis	691.0	L22 Diaper dermatitis
	N/A	L30.9 Dermatitis, unspecified
	N/A	L24.9 Irritant contact dermatitis, unspecified cause
	112.3	B37.2 Candidiasis of skin and nail
	112.1	B37.3 Candidiasis of vulva and vagina
Slips, Falls, and Fractures	N/A	R29.6 Repeated Falls
	V15.88	Z91.81 history of falling
	E880-E884, E885.9, E886.0, E887-E888, E917.7, E917.8, E929.3	W00 – W19 Slipping, tripping, stumbling and falls
	800-826, 830-908, 910-918, 921-929, 950-957, 959, V54.1	S00 – S99 (Injuries of external causes)
Behavioral Disruptions	294.11	F02.81 Alzheimer’s dementia late onset with behavioral disturbance

	294.21	F03.91 Unspecified dementia with behavioral disturbance
	331.19	G31.09 Dementia with Parkinsonism plus F02.81 dementia with behavioral disturbance
	306.8	F59 Unspecified behavioral syndromes associated with physiological disturbances and physical factor
	312.9	F91.9 Conduct disorder

REFERENCES

1. Medicare Payment Advisory Commission, *Report to Congress*, Medicare Payment Advisory Commission, Editor. 2018: Washington D.C. .
2. Medicare Payment Advisory Commission, *Report to Congress*, Medicare Payment Advisory Commission, Editor. 2017: Washington D.C.
3. Kronick Rick, *Projected Coding Intensity in Medicare Advantage Could increase Medicare Spending by \$200 billion over 10 years*. Health Affairs, 2017. **36**(2): p. 320-27.
4. Kronick R. and Welch W.P., *Measuring Coding Intensity in the Medicare Advantage Program*. Medicare and Medicaid Research Review,, 2014. **4**(2): p. E1-E19.
5. Geruso M. and Layton T., *Upcoding: Evidence from Medicare on Squishy Risk Adjustment*. NBER Working Paper 21222, 2018: p. 1-80.
6. Wolfe AR Khouri RK Jr Bhanvadia RR Dropkin BM Joice GA Sanders SC Hudak SJ Morey AF, *Male stress urinary incontinence is often underreported*. Can J Urol., 2021. **28**(2): p. 10589-94.
7. Wallner LP Porten S Meenan RT et al., *Prevalence and severity of undiagnosed urinary incontinence in women*. Am. J. Med., 2009. **122**(11): p. 1037-1042.
8. U.S. Government Accountability Office, *Medicare Advantage: CMS should improve the accuracy of risk score adjustments for diagnostic coding practices*, GAO, Editor. 2012, GAO: Washington D.C.
9. Frogner BK. Anderson GF Cohen RA and Abrams C., *Incorporating New Research into Medicare Risk Adjustment*. Med. Care, 2011. **49**(3): p. 295-300.
10. Jacobs P.D. and Kronick R., *Getting What we Pay For: How do Risk Adjusted Payments to Medicare Advantage Plans Compare with Alternative Measures of Beneficiary Health Risk?* Health Services Research, 2018.
11. Kronick R, *Why Medicare Advantage Plans are being Overpaid by \$200 billion and what to do about it*, in *Health Affairs Blog*, Alan Weil, Editor. 2020, Health Affairs (Millwood).
12. Ian Duncan, *Managing and Measuring Healthcare Intervention Programs (2nd Edition)*. 2014, Winsted CT,: Actex Publications. 446 pages.
13. Leung FW and Schnelle JF, *Urinary and Fecal Incontinence in Nursing Home Residents*. Gastroenterol Clin North Am., 2008. **37**(3): p. 697.
14. Chiarelli PE Mackenzie LA Osmotherly PG, *Urinary incontinence is associated with an increase in falls: a systematic review*. Australian Journal of Physiotherapy, 2009. **55**(2): p. 89-95.
15. Gray M and Guiliano KK, *Incontinence-Associated Dermatitis, Characteristics and Relationship to Pressure Injury: A Multisite Epidemiologic Analysis* J Wound Ostomy Continence Nurs. , 2018. **45**(1): p. 63-7.
16. Ostaszkiwicz J Tomlinson E Hunter K, *The Effects of Education About Urinary Incontinence on Nurses' and Nursing Assistants' Knowledge, Attitudes, Continence Care Practices, and Patient Outcomes: A Systematic Review*. Journal of Wound, Ostomy and Continence Nursing, 2020. **47**(4): p. 365-80.
17. Ge TJ Vetter J Lai HH, *Sleep disturbance and fatigue are associated with more severe urinary incontinence and overactive bladder symptoms*. Female Urology, Urodynamics, Incontinence, and Pelvic Floor. Reconstructive Surgery, 2017. **109**: p. 67-73.
18. Fonda D and Abrams P, *Cure Sometimes, Help Always: Continence Paradigm for all Ages and Conditions*. Neurourology and Urodynamics, 2006. **25**: p. 290-2.

19. Bliss DZ Gurvich O Savik K Eberly LE Harms S and Wyman JF, *Racial and Ethnic Disparities in Time to Cure of Incontinence Present at Nursing Home Admission*. J Health Dispar Res Pract. , 2014. **7**: p. 96-113.
20. Roe B Flanagan L Jack B Barrett J Chung A Shaw C and Williams K, *Systematic review of the management of incontinence and promotion of continence in older people in care homes: descriptive studies with urinary incontinence as primary focus*. J. Adv. Nursing, 2011. **67**: (2): p. 228-250.